VCM
AZN icon

Virtue Capital Management’s AstraZeneca AZN Stock Holding History

Virtue Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-297
Closed -$21K – 215
2018
Q1 		$21K Buy
297
+22
+8% +$1.52K 0.01% 309
2017
Q4 		$19K Buy
+275
New +$18.5K 0.01% 291

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Virtue Capital Management's AZN Position: Q2 2018 in Review

Virtue Capital Management sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 297 shares — an estimated $21K sold.

Virtue Capital Management first reported a position in AZN in Q4 2017 and held it in 2 quarters. The position peaked at $21K in Q1 2018. 530 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

  • Virtue Capital Management reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
  • Virtue Capital Management sold 297 AstraZeneca shares in Q2 2018, an estimated $21K.
  • Virtue Capital Management first reported a position in AstraZeneca in Q4 2017 and held it in 2 quarters.
  • Virtue Capital Management's AstraZeneca position peaked at $21K in Q1 2018.
  • 530 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Virtue Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.